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Purpose: Camrelizumab inhibits PD-1 in non-clinical models and showed typical non-clinical
pharmacokinetic (PK) and safety profiles for an IgG4 monoclonal antibody. We report results
from the First-in-Human Phase 1 trial of camrelizumab in Australian population.
Methods: Camrelizumab was administered to patients with advanced solid tumors who had
failed standard therapies. In the dose-escalation phase (n=23), camrelizumab was adminis-
tered intravenously at 1 mg/kg, 3 mg/kg, 6 mg/kg, and 10 mg/kg every 2 weeks. In dose
expansion (n=26), camrelizumab was given at 200 mg or 600 mg every 4 weeks.
Results: Two dose-limiting toxicities were observed during dose escalation: transaminase
elevation and diarrhea (both grade 3). Overall, treatment-related adverse events were con-
sistent with the expected toxicity profile of immune checkpoint inhibition, with the striking
exception of the dose-related development of angiomatous skin lesions characterized as
reactive cutaneous capillary endothelial proliferation. The PK profile showed a dose-
progressive increase in half-life from 3 days at 1 mg/kg to 7 days at 10 mg/kg. Moreover,
receptor occupancy assays showed a PD-1 occupancy of >50% in most patients out to 28
days post-dose. The objective response rate was 15.2% (95% CI 6.3–28.9).
Conclusion: Camrelizumab has manageable toxicity and encouraging preliminary antitumor
activity in advanced solid tumors in Australia.
Clinical Trial Registration: ClinicalTrials.gov Identifier: NCT02492789.
Keywords: PD-1, monoclonal antibody, first-in-human dose study, cancer, reactive
cutaneous capillary endothelial proliferation
Background
Programmed cell death protein 1 (PD-1), also known as CD279, is an immune-
inhibitory receptor and a member of the immunoglobulin superfamily. It is
expressed on a variety of immune cells including CD8+ cytotoxic T cells and is
involved in the regulation of peripheral tolerance.1,2 Binding of its ligands PD-L1
and/or PD-L2 can lead to a dampening of T cell activation and immune reactions,
and expression of PD-L1 on tumor cells often allows for a successful immune-
escape. Inhibition of PD-1 can lead to re-invigoration of T cell activity and can
enhance the recruitment of effector T cells in otherwise poorly immunogenic
tumors.3–5 These and similar observations led to the development of monoclonal
antibodies blocking PD-1 and PD-L1 for the treatment of cancer.6–8 One such
monoclonal antibody is camrelizumab, a humanized IgG4 that binds PD-1 at
a high affinity of 3 nM as determined by the BiaCore T200 assay. Furthermore,
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the camrelizumab inhibited the binding interaction of PD-
1 and PD-L1 at an IC50 of 0.70 nM. In a T cell prolifera-
tion assay using tuberculin treated peripheral blood mono-
nuclear cells, camrelizumab induced a T cell proliferation
at an EC50 of 0.11 nM. Finally, in a similar assay measur-
ing IFN-gamma secretion, camrelizumab induced IFN-
gamma production at an EC50 of 0.38 nM.
Camrelizumab had the appropriate safety and pharmaco-
kinetic properties in non-clinical studies to justify its clin-
ical investigation in cancer patients.
Several studies reported the clinical potential of cam-
relizumab due to its promising antitumor activity and
manageable toxicity profile in multiple cancers, but these
clinical evidences were only limited to Chinese
population.9–11 Here, we report the results from the First-
in-Human (FiH) Phase 1 study of camrelizumab conducted
in Australia, which was launched preceding those camre-
lizumab trials in China, in patients with advanced cancer.
Methods
Experimental Design
The study was conducted at five sites in Australia.
Camrelizumab was investigated in a FiH, 3+3 dose-
escalation and dose-expansion phase 1 study to evaluate
the safety and tolerability of camrelizumab in patients with
advanced solid tumors (Supplementary Figure 1). In dose-
escalation phase, camrelizumab was given at a dose of
1 mg/kg, 3 mg/kg, 6 mg/kg, and 10 mg/kg every 2
weeks (Q2W) with the intention of determining the max-
imum tolerated dose (MTD). In dose-expansion phase,
cohort was expanded to further explore the clinical safety
and preliminary antitumor activity of camrelizumab at the
recommended dose identified from dose-escalation phase
in four tumor types: endometrial carcinoma, thymic carci-
noma, biliary tract carcinoma (BTC), and carcinoma of
unknown primary (CUP).
Patients
In the dose-escalation phase, patients with histologically or
cytologically confirmed advanced or metastatic solid
tumors who had relapsed after or were refractory to stan-
dard therapies, were intolerant to standard therapies or had
refused standard therapy were enrolled. In dose-expansion
phase, patients with four tumor types were enrolled.
Endometrial carcinoma patients with histologically con-
firmed advanced or metastatic carcinoma (sarcomas and
mesenchymal tumors were excluded) that had relapsed
after or were refractory to at least 1 prior standard therapy
in the metastatic setting, were intolerant to standard thera-
pies or refused standard therapy were included. In addi-
tion, patients with disease recurrence within 12 months of
completion of adjuvant therapy were eligible. Thymic
carcinoma patients had histologically or cytologically con-
firmed advanced or metastatic disease12 based on local
guidelines. Biliary tract carcinoma patients had histologi-
cally or cytologically confirmed advanced or metastatic
extrahepatic cholangiocarcinoma or carcinoma of the
ampulla of Vater and had relapsed after or were refractory
to at least 1 prior standard therapy, were intolerant to
standard therapies or refused standard therapy. Patients
with cancer of unknown primary per European Society
for Medical Oncology (ESMO) guidelines13 were also
included.
Eligible patients had an Eastern Cooperative Oncology
Group (ECOG) Performance Status of 0 or 1; a life expec-
tancy ≥12 weeks; measurable lesion(s) according to
Response Evaluation Criteria in Solid Tumors (RECIST)
v1.1; adequate laboratory parameters. Female patients
agreed not to become pregnant or to breast-feed from the
beginning of the study screening period through at least 3
months after receiving the last dose of study treatment were
enrolled. Both men and women of reproductive potential
agreed to employ a highly effective method of contraception.
Patients with any active autoimmune disease or history
of autoimmune disease or history of a syndrome that
required systemic steroids or immunosuppressive medica-
tions (except for patients with vitiligo or resolved childhood
asthma/atopy) were excluded. Also, patients with
a concurrent medical condition requiring the use of immu-
nosuppressive medications, or immunosuppressive doses of
systemic or topical corticosteroids were excluded. Patients
with active central nervous system (CNS) metastases were
excluded, as well as patients who had an uncontrolled clini-
cally significant medical condition, had received prior sys-
temic chemotherapy, radiotherapy, immunotherapy, hormone
therapy, surgery or targeted therapy within 4 weeks before
the study drug administration or had any unresolved adverse
events (AEs) > Common Terminology Criteria for Adverse
Events (CTCAE) Grade 1 (with the exception of stable
chronic toxicities not expected to resolve).
Treatment: Dose and Dose Levels
Camrelizumab, a new fully humanized IgG4 monoclonal
anti-PD-1 antibody, was produced as a lyophilized powder.
It was reconstituted in water and diluted in 5% dextrose to
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a final concentration of between 0.5 mg/mL and 10 mg/
mL, before administration as an IV infusion over 30 mins.
In the dose-escalation phase, the dose of camrelizumab
was determined based on body weight (1 mg/kg, 3 mg/
kg, 6 mg/kg, or 10 mg/kg). Camrelizumab was adminis-
tered on Day 1 of Cycle 1 (each cycle is 4 weeks) and
Q2W from Cycle 2. In the dose-expansion phase, camre-
lizumab was administered at a flat dose of 200 mg every 4
weeks (Q4W), except for the first 3 subjects enrolled,
whose initial dose was 600 mg Q4W.
Dose Escalation and Dose-Limiting
Toxicities (DLTs)
The safety and tolerability of camrelizumab was assessed
by ongoing reviews of clinical laboratory tests, ECOG
performance status, physical examination, electrocardio-
gram (ECG), and adverse events. All immune-related
adverse events (irAEs) were classified as AEs of special
interest (AESIs) if the investigator deemed that there was
a likely causal relationship to camrelizumab. Evaluations
of skin toxicities were conducted by skin photography and
histopathology as guided by clinical assessment.
In dose-escalation phase, three to six patients were
enrolled in each dose cohort and assessed for DLTs from
the first infusion of the study drug through the end of
Cycle 1 (28 days after the first dose). Any patient with-
drawn from the study before the completion of the first
cycle for any reason other than a DLT was replaced unless
there were already sufficient DLT-evaluable patients in
that cohort. If none of the initial three patients at a dose
level experienced a DLT, then dose escalation to the next
planned level could proceed. If one of three patients in
a dose cohort experienced a DLT, three additional patients
were enrolled in the cohort and if no DLT was observed in
these patients, dose escalation could proceed. If two DLTs
were observed at a given dose level, an intermediate dose
level could be considered by the Safety Monitoring
Committee (SMC) for testing as the MTD.
Severity of AEs was graded according to National
Cancer Institute (NCI)-CTCAE version 4.0. In dose-
escalation and expansion phase, the occurrence of any of
the following toxicities during Cycle 1 (28 days from the
first infusion) was considered a DLT, if judged by the
investigator to be probably or definitely related to study
drug administration: (a) Grade ≥2 uveitis; (b) Grade ≥2
pneumonitis that persisted for >7 days despite treatment
with systemic corticosteroids (subjects with Grades 3 and
4 pneumonitis were to be discontinued from study treat-
ment); (c) Grade ≥3 nonhematologic AE with Grade 3
AEs considered dose-limiting when they required medical
intervention, resulted in hospitalization, lasted >3 days
(Grade 3 fatigue >7 days) despite optimal supportive
care or were a clinically significant laboratory abnormal-
ity; (d) Grade ≥3 hematologic toxicity.
AEs were not considered DLTs if there was a clear,
well-documented, alternative explanation for the AE. The
SMC could also consider AEs as DLTs if they occurred
after Cycle 1 and appeared to result from delayed or
cumulative toxicities.
Safety and Efficacy Assessments
Safety was evaluated in patients who received at least one
dose of camrelizumab. All reported adverse events were
coded according to MedDRA, version 18.1 and graded as
per CTCAE version 4.0. All concomitant medications
were documented throughout the patient’s participation in
the study. The anti-tumor responses were assessed per
RECIST 1.1.
Interim Analyses
While no formal interim analyses were conducted, the
SMC reviewed the comprehensive data on an ongoing
basis. During this review, safety and emerging preclinical
and efficacy data were reviewed to decide the dose and
dose regimen during the conduct of the trial. At each dose
level, the SMC reviewed all data and decided on commen-
cing the next dose level as well on the recommended
Phase 2 dose and dose regimen.
Bioanalytical Methods
Serum samples to determine the levels of camrelizumab and
its pharmacokinetic (PK) profile were collected during Cycle
1 at Days 1, 2, 3, 8, 15, and 22 and during the remaining
cycles at Days 1 and 15. Camrelizumab was directly detected
with a specific immune assay, the results were graphically
analyzed and then pooled for final analyses using nonlinear
mixed-effect modeling (NONMEM, version 7.3).
PD-1 receptor occupancy (RO) assessment using
PD-1–expressing JURKAT cells (ATCC® Number:
TIB-152TM): We first assessed the serum of patients for
the presence of camrelizumab and its ability to bind to
PD-1 receptors on JURKAT cells. Serum samples were
collected at the same time points as for the PK samples
(see above) and incubated with a fixed amount of PD-1–
expressing JURKAT cells for 60 mins, followed by
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incubation with 3 μg/mL fluorescein-labeled camrelizu-
mab for 30 mins, and RO was determined by flow
cytometry.
Whole Blood Processing
The fresh human blood samples (3 mL) were aliquoted
into a 50 mL centrifuge tube. A 30 mL 1× BD FACS
Lysing (Cat No.: 555899, San Jose, CA) was added and
the tube was inverted several times to confirm the effec-
tive mixing of the blood and FACS Lysing solution.
Samples were incubated at room temperature for
10–12 mins. Samples were centrifuged 400× g, 5 mins
at room temperature and the supernatant was discarded.
The tube was filled with 30 mL DPBS, and centrifuge for
5 mins at 400× g. The supernatant was discarded, the
cells re-suspended in 1.5 mL DPBS, counted and used
immediately in the assays below.
Receptor Occupancy Assay
Approximately 4 × 105 cells were plated in a 96-well
U-bottom plate, and either human IgG4 protein (Abcam
Cat. No.: Ab90286, Cambridge, MA) or camrelizumab-
Fluorescein (provided by Incyte, Wilmington, DE) was
added at 20 μg/mL final concentration. Samples were
incubated at room temperature for 30 mins. The plate
was centrifuged at 300× g for 5 mins and the supernatant
was discarded. Samples were stained: Stain I at the follow-
ing dilutions in PBS/0.5% FCS: 1/1000 eFluor 710 live
dead (Invitrogen Cat. No.: 65-0865-18, Carlsbad, CA);
1/150 anti-huCD4 (OCT4)-BV421 (Biolegend Cat. No.:
317434, San Diego, CA); 1/150 anti-huCD3-(SK7)-
BV510 (Biolegend Cat. No.: 344828); 1/150 anti-huCD8-
PeCy7 (Biolegend Cat. No.: 344712); 1/100 anti-IgG4-PE
(Southern Biotech Cat. No.: 9200–09, Birmingham, AL).
Samples were incubated at 4°C for 15 mins in the dark.
Samples were washed with DPBS followed by centrifuga-
tion at 300× g for 5 mins and the supernatant was dis-
carded. Samples were re-suspended in 100 µL DPBS and
immediately run on the FACs Canto. Analysis was per-
formed using FlowJo software (version 10; Treestar,
Ashland, OR). Assays were performed at least in duplicate
or in triplicate where sufficient cells were available.
Tumor Tissue
Where available, tumor tissue was assessed for PD-L1 by
immunohistochemistry (22C3 clone for IHC; Indivumed,
Hamburg, Germany).
Statistical Analysis
In the dose-escalation phase, no sample size calculation
for efficacy was used. The enrollment was based on stan-
dard safety and tolerability evaluation. In the dose-
expansion phase, approximately 52 patients were to be
enrolled (approximately 13 patients in each of four tumor-
expansion cohorts). This was determined from a Bayesian
analysis based on a prior probability of 32% that the
response rate is at least 20% (prior response rate as Beta
[0.2, 0.8]), and assuming 3 responses are observed in
a cohort of 13 patients, then there is a 56% probability
that the true response rate is at least 20%.
The objective response rate (ORR) and disease control
rate (DCR) per RECIST 1.1 along with the 95% Clopper–
Pearson confidence interval (CI) were tabulated by dose
levels in dose-escalation phase and expansion phase com-
bined, and by tumor type in expansion phase. Progression-
free survival (PFS) was analyzed using the Kaplan–Meier
method, along with median and 95% confidence intervals
for the median.14 Laboratory parameters were reported as
percentages, cells/μL, GI/L, U/L, pg/mL, where appropri-
ate and indicated on tables/figures.
Results
Patient Disposition and Characteristics
Patients were enrolled and treated in this FiH study between
October 2015 and February 2017 (with one patient still on
treatment in May 2019) at five centers in Australia (three
centers participating in dose-escalation phase only). A total
of 52 patients were screened, of which 49 were enrolled and
treated with camrelizumab. Of the 49 patients, 23 patients
were treated in the dose-escalation phase and 26 in dose-
expansion phase (Supplementary Figure 1). The dose expo-
sure to camrelizumab in each sub-group was presented in
Supplementary Table 1. As of data cutoff, four (8.2%)
patients were still receiving treatment. The reasons for
treatment discontinuation were radiographic progression
(n=26, 53.1%), clinical progression (n=13, 26.5%), intoler-
able toxicity/AE (n=3, 6.1%), investigator discretion (n=2,
4.1%), and death (n=1, 2.0%).
Baseline characteristics were presented in Table 1.
Thirty-two of 49 patients were female (65.3%) and the
majority of patients were Caucasian (77.6%). The median
age was 60 years (range, 32–80), with 67.3% of patients
being younger than 65 years (33/49). An ECOG
Performance Status of 1 was reported for 63.3% of all
patients (31/49). Metastatic sites included lung, liver,
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lymph nodes and other sites. The median time since
diagnosis across all patients was 1.5 years (range, 0.3–
10.4). Patients received a median of three (range, 1–20)
prior anti-cancer therapies. In the dose-escalation cohort,
all patients were diagnosed with advanced solid tumors,
including ovarian, breast, head and neck, colorectal and
other carcinomas. In the dose-expansion cohort, there
were six endometrial carcinomas, 11 biliary tract carci-
nomas, six other carcinomas and three CUP.
Safety Outcomes
All 49 treated patients were evaluated for safety and toler-
ability. During the dose-escalation phase, there were two
instances where DLTs were observed requiring the
Table 1 Demographics and Other Baseline Characteristics
Characteristics Dose-Escalation Dose-
Expansion
Total
(n=49)
1 mg/kg
(n=6)
3 mg/kg
(n=6)
6 mg/kg
(n=4)
10 mg/kg
(n=7)
200 mg
(n=26)
Age, years 54 (32–64) 64 (51–73) 65 (45–69) 56 (48–73) 55 (35–80) 60 (32–80)
Sex, n (%)
Male 1 (16.7) 3 (50.0) 1 (25.0) 1 (14.3) 11 (42.3) 17 (34.7)
Female 5 (83.3) 3 (50.0) 3 (75.0) 6 (85.7) 15 (57.7) 32 (65.3)
Ethnicity, n (%)
Caucasian 6 (100.0) 6 (100.0) 3 (75.0) 6 (85.7) 17 (65.4) 38 (77.6)
Asian 0 0 1 (25.0) 1 (14.3) 7 (26.9) 9 (18.4)
Other 0 0 0 0 2 (7.7) 2 (4.1)
ECOG Performance status at baseline,
n (%)
0 3 (50.0) 1 (16.7) 1 (25.0) 1 (14.3) 12 (46.2) 18 (36.7)
1 3 (50.0) 5 (83.3) 3 (75.0) 6 (85.7) 14 (53.8) 31 (63.3)
Solid tumor cancer type, n (%)
Breast 1 (16.7) 0 0 1 (14.3) 0 2 (4.1)
CUP 0 0 0 0 3 (11.5) 3 (6.1)
Cervical 1 (16.7) 0 0 0 0 1 (2.0)
Colorectal 1 (16.7) 1 (16.7) 0 0 0 2 (4.1)
Endometrial 0 0 0 1 (14.3) 6 (23.1) 7 (14.3)
Esophageal 0 0 0 1 (14.3) 0 1 (2.0)
BTC 0 0 0 0 11 (42.3) 11 (22.4)
Gastric 0 1 (16.7) 0 0 0 1 (2.0)
GE junction 1 (16.7) 0 0 0 0 1 (2.0)
Head and neck 0 1 (16.7) 1 (25.0) 0 0 2 (4.1)
Neuroendocrine 0 0 1 (25.0) 0 0 1 (2.0)
Ovarian 0 0 1 (25.0) 2 (28.6) 0 3 (6.1)
Penile 0 1 (16.7) 0 0 0 1 (2.0)
Renal cell 0 0 1 (25.0) 0 0 1 (2.0)
Sarcoma 0 1 (16.7) 0 0 0 1 (2.0)
Thyroid cancer 0 0 0 1 (14.3) 0 1 (2.0)
Urothelial/Bladder 0 0 0 1 (14.3) 0 1 (2.0)
Uterine 1 (16.7) 0 0 0 0 1 (2.0)
Other 1 (16.7) 1 (16.7) 0 0 6 (23.1) 8 (16.3)
Number of Prior Anti-Cancer Therapies
n 6 6 4 6 26 48
Median (range) 4.0 (1–12) 3.5 (1–20) 3.5 (2–6) 3.5 (2–11) 3.0 (1–6) 3.0 (1–20)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; n, number of patients; CUP, carcinoma of unknown primary; BTC, biliary tract carcinoma; GE,
gastroesophageal.
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expansion of the cohort: during the first cohort (1 mg/kg)
and during the second cohort (3 mg/kg). The DLT at 1 mg/
kg occurred after the first dose and was Grade 3 aspartate
aminotransferase (AST) increased and alanine
aminotransferase (ALT) increased (Supplementary
Table 2). Glucocorticoid treatment was commenced and
transaminase levels promptly returned to normal. Re-
treatment with camrelizumab did not result in additional
liver AEs. A DLT of diarrhea was observed in a patient
with gastric cancer after the first dose of camrelizumab at
3 mg/kg. This resolved after starting glucocorticoid ther-
apy. The patient was not re-treated with camrelizumab
because of tumor progression. Because of these DLTs,
the first and second cohorts were expanded to 6 patients
and it was decided to add an intermediate dose level at
6 mg/kg before proceeding to the 10 mg/kg dose level.
All patients (49/49, 100%) experienced at least one all-
causality adverse event during this study (Table 2). The most
commonly reported AEs included reactive cutaneous capil-
lary endothelial proliferation (RCCEP; 31/49, 63.2%), fati-
gue (18/49; 36.7%), diarrhea (11/49; 22.4%), nausea (10/49;
20.4%), and vomiting (9/49; 18.4%). Nineteen (38.8%)
patients reported AEs of Grade ≥3. Subjects with any serious
AE (SAE) occurred in 21 (42.9%) patients, with the most
common being disease progression (3; 6.1%), cellulitis (2;
4.1%), hepatic failure (2; 4.1%), respiratory tract infection (2;
4.1%), and small intestinal obstruction (2; 4.1%). Treatment-
related AEs occurred in 39 (79.6%) of 49 patients and 11
(22.4%) patients discontinued treatment due to an AE. Six of
the 20 subject deaths were due to a fatal AE, but no deaths
were deemed to be related to camrelizumab and considered
to be a result of disease progression.
Six (12.2%) patients reported a total of eight immune-
related AEs (irAEs), which were collected as AEs of special
interest (AESI), after administration of camrelizumab,
including arthropathy (Grade 2), diarrhea (Grade 3), auto-
immune hepatitis (Grade 3), pneumonitis (Grade 3), hypopi-
tuitarism (Grade 3), ALT elevation (Grade 3), AST elevation
(Grade 3) and pancreatitis (Grade 2) (Supplementary
Table 2). There was no clear association between the inci-
dence and severity of irAEs and camrelizumab dose.
In contrast to the reported effects of other anti-PD-1
antibodies, camrelizumab treatment was associated with the
development of focal vascular lesions of the skin character-
ized as Grade 1 or 2 RCCEP. In a minority of patients,
RCCEP also involved the oral mucosa. Although numeri-
cally higher dose levels of camrelizumab were not associated
with a higher incidence and severity of RCCEP, the overall
presentation of RCCEP and extent over several areas of the
body surface appeared to be worse as the doses progressed.
Patients were particularly concerned at their physical appear-
ance if they received the highest doses of camrelizumab.
Patients reported the lesions within the first 10 weeks of
starting camrelizumab treatment and lesions persisted for
many months in some cases. The lesions mostly occurred
on the upper body of study patients (torso, arms, head and
neck). In three patients administered camrelizumab at 1 or
3 mg/kg Q2W for more than 6 months, the RCCEP sponta-
neously regressed despite ongoing study drug treatment. The
RCCEP affecting three other patients (treated at 1 mg/kg,
3 mg/kg or 6 mg/kg Q2W) largely resolved within 4 weeks of
discontinuing study drug. One of these patients subsequently
restarted camrelizumab and RCCEP re-growth was observed
at one of the previous sites while the other lesions gradually
regressed further (Figure 1). No internal bleeding was
reported, and hemoglobin levels remained stable or increased
despite the development of RCCEP.
Pharmacokinetics
The pharmacokinetic profile of camrelizumab is consistent
with typical therapeutic antibodies (Figure 2A and B).
Non-compartmental analysis indicated a half-life of three
to 10 days from 1 mg/kg to 10 mg/kg after a single IV
infusion. While Cmax increased proportionally to dose
from 1 mg/kg to 10 mg/kg, AUC0-∞ showed supra-
linearity over the same dose range. Low inter-subject
variability was observed for PK exposures up to 6 mg/kg
Q2W, and higher interpatient variability was observed at
10 mg/kg Q2W (Supplementary Table 3). The mean expo-
sure profile for the 200 mg flat dose is essentially super-
imposable on that of the 3 mg/kg profile.
Receptor Occupancy (RO) of PD-1
In the first three dose-escalation cohorts, we assessed RO of
circulating camrelizumab in JURKAT cells and tracked with
plasma half-life in patients. In addition, starting with dose
level 10 mg/kg Q2W (dose-escalation phase) and in all
subsequently treated patients (dose-expansion phase), we
measured PD-1 RO on patient circulating CD8+ and CD4+
T cells. This showed that RO remained greater than 50%
during the 28 days after the initial camrelizumab dose in
most patients, with higher levels at earlier post-dose time-
points (Figure 2C and D). After completing Cycle 1, the RO
evaluation was performed predose every 4 weeks and these
levels were generally similar to those at day 28.
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Figure 1 Development of RCCEP in a breast cancer patient treated with 1 mg/kg of camrelizumab. (A, B) The initial RCCEP lesion was observed at approximately 2 weeks
after the first dose of study drug on the lateral chest followed by lesions on the anterior chest. (C–E) Since this patient showed stable disease (SD) at Day 56 and
subsequently a partial response (PR) at Day 112, she continued to receive camrelizumab and additional RCCEP appeared on her upper trunk and neck. (F–H) After
interrupting camrelizumab treatment for 28 days in response to cellulitis requiring hospitalization, there was substantial regression of the RCCEP. (I) Upon re-starting
camrelizumab, one of the previous RCCEP lesions re-grew without progression of RCCEP lesions elsewhere. Blue solid arrow represents treatment time, while hatched
blue color represents the treatment pause. Black arrows connect the timing of RCCEP photographs and the treatment timeline.
Abbreviations: SD, stable disease; PR, partial response.
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Figure 2 Serum camrelizumab concentration–time curve and receptor occupancy (RO). (A,B) Serum camrelizumab concentration–time curve after single IV infusion in linear (A)
and semi-logarithmic (B) scale during the first 28 days after the initial infusion. (C, D) Camrelizumab RO on CD4+ (C) and CD8+ (D) T Cells at the 10 mg/kg dose level and 200 mg
flat dose level for the entire treatment period. Blood samples were obtained at the time points shown out to 28 days after the first dose and then prior to the second and
subsequent dose (every 28 days). Each line represents an individual patient, with red lines indicating 10 mg/kg treated patients and blue lines indicating 200 mg flat dosing.
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Efficacy Outcomes
Among the 46 patients included in the efficacy analysis,
one (2.2%) subject achieved a complete response (biliary
tract carcinoma). Six (13.0%) additional patients had
a partial response (one breast carcinoma, one parotid car-
cinoma, one renal cell carcinoma, one urothelial carci-
noma, one ovarian carcinoma and one endometrial
carcinoma), eight (17.4%) patients had stable disease,
and 25 (54.3%) patients had disease progression as their
best response (Table 3). In additional 6 patients, there was
no scan to perform a RECIST assessment. Thus, the ORR
and DCR for the entire study population were 15.2% (95%
CI 6.3–28.9) and 32.6% (95% CI 19.5–48.0), respectively.
A waterfall plot of best reductions from baseline in target-
lesion size is shown in Figure 3A. No clear association
between camrelizumab dose and tumor response was evi-
dent. A spider plot of changes from baseline in the size of
target lesions over time is presented in Figure 3B. The
estimated median PFS was 1.9 months (95% CI 1.8–3.1)
and the occurrence of RCCEP across all doses appeared
not to be correlated with tumor responses (Figure 3C).
Discussion
We reported the first FiH trial conducted outside of China.
In this FiH study, we evaluated the clinical safety, PK
profile, and initial efficacy of camrelizumab, a novel
monoclonal antibody against PD-1 with a binding affinity
of 3 nM, which is comparable to that of other
monoclonal antibodies directed against PD-1 such as
pembrolizumab.15,16 The Australian patients in this study
had exhausted all standard therapies and most had received
at least two prior lines of therapy. Hence, the ORR of 15%
was consistent with response rates reported for other PD-1
inhibitors that were investigated in a wide range of different
tumor types and in FiH dose studies.15,16
Notwithstanding these similarities, there were some dif-
ferences compared to other PD-1 inhibitors. First, responses
were observed in patients with no or very low expression of
PD-L1 expression in their tumor samples (Supplementary
Table 4). Because of the availability of tumor tissue from
12 patients, this observation will need to be further investi-
gated. Second, even as camrelizumab was declining in con-
centration due to its short half-life, the concomitantly
measured RO remained elevated at above 50% in most
patients. In one patient who stopped taking camrelizumab,
the RO remained unchanged for close to 3 months before RO
levels started to decline. Third, we observed RCCEP,
a unique feature so far not reported for other PD-1 inhibitors.
While camrelizumab had rates of all-cause AEs Grade 1/2 of
75% and Grade 3/4 of 25% and an AESI (or irAEs) rate of
19% (8/42) similar to other PD-1 inhibitors investigated in
FiH studies,15,17 we observed an increasing number of
patients reporting RCCEP. These RCCEPs were distinct
from the types of skin-related toxicity reported for approved
Table 3 Response and Survival Data
Escalation Phase Expansion
Phase
Total (n=46)
1 mg/kg (n=5) 3 mg/kg (n=6) 6 mg/kg
(n=4)
10 mg/kg
(n=6)
200 mg (n=25)
Response per RECIST,
n (%)
Complete Response 0 0 0 0 1 (4.0)* 1 (2.2)
Partial Response 2 (40.0) 0 1 (25.0) 2 (33.3) 1 (4.0)# 6 (13.0)
Stable Disease 1 (20.0) 4 (66.7) 0 0 3 (12.0)† 8 (17.4)
Progressive Disease 2 (40.0) 1 (16.7) 3 (75.0) 4 (66.7) 15 (60.0)‡ 25 (54.3)
Not Evaluable 0 1 (16.7) 0 0 5 (20.0)§ 6 (13.0)
ORR, % (95% CI) 40.0 (5.3–85.3) 0 (0–45.9) 25.0 (0.6–80.6) 33.3 (4.3–77.7) 8.0 (1.0–26.0)* 15.2 (6.3–28.9)
DCR, % (95% CI) 60.0 (14.7–94.7) 66.7 (22.3–95.7) 25.0 (0.6–80.6) 33.3 (4.3–77.7) 20.0 (6.8–40.7) 32.6 (19.5–48.0)
DoR, months (95% CI) NR (5.4–NR) NR (NR–NR) NR (NR–NR) 1.2 (NR–NR) NR (NR–NR) NR (1.2–NR)
PFS, months (95% CI) 7.2 (1.7–NR) 3.5 (1.7–NR) 1.8 (1.7–NR) 1.8 (0.7–NR) 1.9 (1.8–2.9) 1.9 (1.7–3.1)
Notes: *This patient had biliary tract carcinoma. #This patient had endometrial carcinoma. †It included one thymic carcinoma, one biliary tract carcinoma, and one
carcinoma of unknown primary. ‡It contained five endometrial carcinomas, six biliary tract carcinomas, and four carcinomas of unknown primary. §It included three biliary
tract carcinomas, and two carcinomas of unknown primary. *The number of patients with complete or partial response in the dose expansion cohort by solid tumour cancer
type for endometrial carcinoma, thymic carcinoma, biliary tract carcinoma and carcinoma of unknown primary were 1 of 6, 0 of 2, 1 of 11, and 0 of 7, respectively.
Abbreviations: NR, Not reached; DCR, disease control rate; DoR, duration response; n, number of subjects; ORR, objective response rate; PFS, progression-free survival.
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PD-1 inhibitors.18–20While the RCCEPswere not considered
DLTs or life-threatening, patients were often concerned about
their physical appearance. In search of understanding the
mechanism of these RCCEPs, we found that similar
RCCEP had been reported for patients treated with the
VEGFR2 inhibitors tanibirumab (about 50% of patients)
and CDP749 (23% of patients)21,22 and in a single case for
ramucirumab.23 Because of this clinical similarity to tanibir-
umab or CDP749, we investigated the binding affinity of
camrelizumab to VEGFR2. In contrast to tanibirumab, cam-
relizumab bound to VEGFR2 at approximately 2.8 μM in
a BiaCore assay, and it showed no significant binding in
cellular assays. Alternatively, we considered that camrelizu-
mab may target PD-1 expressing cells in the skin, which in
turn may produce VEGF via chemokine release.24 For exam-
ple, infantile or toxicity-induced RCCEP are thought to be
partially induced by such an immune-related activation, but
a role of PD-1 has not been reported.24–26 A treatment with
topical propranolol as indicated in some patients with infan-
tile RCCEP was not attempted in this trial.27 We also con-
sidered the possibility that genetic polymorphisms of
VEGFR2 may pre-dispose Caucasian patients to developing
RCCEP. However, Chinese patients treated with camrelizu-
mab had similar skin toxicities, including similar times from
120
110
100
90
80
70
60
50
40
30
20
0
10
-10
-20
-40
-50
-80
-30
-60
-70
-90
-100
0 100 200 300 400 500 600 700 800 900 10001100
Time (day)
C
h
an
g
e 
fr
o
m
 B
as
el
in
e 
(p
er
ce
n
ta
g
e)
20%
-30%
100
80
60
40
20
0
-20
-40
-60
-80
-100
C
h
an
g
e 
fr
o
m
 B
as
el
in
e 
(p
er
ce
n
ta
g
e)
A
B
1 mg/kg
3 mg/kg
6 mg/kg
10 mg/kg
200 mg/kg
In
d
iv
id
u
al
 s
u
b
je
ct
s
0 5 10 15 20 25 30 35 40
RCCEP
1 mg/kg
6 mg/kg
200 mg/kg
3 mg/kg
10 mg/kg
PR
SD
PD
CR
Death
Time from first dose (month)
C
Figure 3 Clinical response. (A) Waterfall plot of the maximal percentage reduction from baseline of the sum of longest diameters of target lesions for both dose-escalation
and expansion phases. (B) Spider plot of the percentage change from baseline in the sum of longest diameters of target lesions over time. (C) Duration of treatment (n=46).
Each individual patient treatment time is plotted from time of first dose (x-axis) based on the dose level and dose regimen. Patients with partial responses (green square),
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the start of treatment to onset and the disappearances of
RCCEP after longer treatment periods, including patients
who were still receiving camrelizumab.11,28 Given these
observations, we also cannot exclude that camrelizumab
may interact with an unknown ligand. Recent studies have
suggested that despite similarities in binding affinity, PD-1
inhibitors are folded differently and this may have subtle
implications on their clinical profile.29 Recently, a group
investigated the possibility of whether the protein folding
of camrelizumab may expose sequences that activate
VEGFR2.30 As these RCCEP are histologically similar to
pyogenic granulomas,31 then the origin of the RCCEP may
be the result of an initial mechanical injury (for example,
friction), and camrelizumab might block the subsequent
healing process.
The limitations of this FiH study include that no pre-
treatment PD-L1 status assessment was mandatory.
Available tumor tissue was assessed in a retrospective man-
ner and therefore these data are hypothesis-generating. In
addition, the underlying mechanism of the pathogenesis of
RCCEP needs further investigation.
In summary, camrelizumab appears to be an active PD-1
inhibitor with acceptable skin and other toxicities when
dosed at 200 mg Q4W in Australian population. However,
the more frequent dosing of 200 mg Q2W appears to be an
acceptable alternative as several studies in Chinese patients
have shown.10,32-38 This larger experience of camrelizumab
in Chinese patients has been the basis of its approval in
China for the treatment of patients with Hodgkin’s
Disease.10,34,39 Since all studies were conducted in
Chinese population so far, our study provided clinical evi-
dence in Australian and expanded the generalizability of
camrelizumab in solid tumors in patients outside of China.
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